Value through Innovation27 July 2016

Clinical Study Results

  • BI 860585 - Neoplasms
    Clinical Study Number 1325.1
    Study Indication Neoplasms
    Product BI 860585
    Generic Name BI 860585
    Lab Code BI 860585
    Clinical Phase I
    Study Title

    An open-label, Phase I, dose-finding study of BI 860585 administered orally in a continuous dosing schedule as a single agent and in combination with exemestane or with paclitaxel in patients with various advanced and/or metastatic solid tumours

    Study Document Trial synopsis 1325.1 english Lay summary 1325.1 english

Clinical Trial Registry and structured study results. Find here protocol information for all clinical study types.

European Trial Register of EU studies.